Butterfly Network, Inc. BFLY R2KR3KPHARMA
Company Overview
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Revenue has grown at a 23.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $97.61M (+19.0% YoY); net profit $-77.06M.
- Trailing 12 Months Year-on-year growth — revenue +39.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 23.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 23.45% |
| 1 Year: | 39.50% |
Stock Price Performance
| 1 Year: | +338.96% |
| 6 Months: | +26.83% |
| 3 Months: | -4.38% |
| 1 Month: | -28.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)36.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 23.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BFLY Butterfly Network, Inc. R2KR3KPHARMA | 6.76 | -23.31 | $1.66B | 0.00% | -37.34% | -35.46% | 23.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.67M | 11.79M | 10.13M | 12.44M | 16.51M | 14.62M | 15.57M | 19.21M | 19.62M | 15.48M | 18.49M | 15.42M | 17.66M | 21.49M | 20.56M | - | 23.38M | 21.49M | 31.51M | 26.53M | 32.61M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.49M | 25.25M | 10.29M | 8.24M | 9.32M |
| Gross Profit | -836.00K | 165.00K | -69.25M | 6.42M | 8.22M | -5.12M | 8.34M | 10.57M | 10.99M | 9.09M | 10.92M | 9.38M | 10.28M | 12.59M | 12.23M | - | 14.89M | -3.76M | 21.22M | 18.29M | 23.29M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.99M | 31.38M | 37.93M | 32.16M | 36.95M |
| Operating Income | -24.51M | -23.07M | -91.83M | -53.75M | -36.69M | -56.99M | -49.53M | -48.45M | -46.03M | -35.05M | -31.26M | -32.56M | -22.62M | -17.23M | -17.25M | - | -16.10M | -35.13M | -16.71M | -13.87M | -13.66M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.36M | -31.68M | -13.08M | -10.59M | -10.97M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 368.00K | 385.00K | 390.00K | 279.00K | 282.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.81M | -33.95M | -15.22M | -12.68M | -12.91M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00K | 16.00K | 67.00K | 0 | 0 |
| Net Income | -24.35M | -23.24M | -92.21M | -690.00K | -2.94M | -13.56M | -44.48M | -35.80M | -54.74M | -33.54M | -28.67M | -27.37M | -21.76M | -15.71M | -16.92M | - | -13.83M | -33.97M | -15.29M | -12.68M | -12.91M |
| Diluted EPS | - | - | -15.20 | -0.01 | -0.02 | -0.07 | -0.22 | -0.18 | -0.27 | -0.17 | -0.14 | -0.13 | -0.10 | -0.07 | -0.08 | - | -0.06 | -0.13 | -0.06 | -0.05 | -0.05 |
| R&D Expense | 12.52M | 11.94M | 11.97M | 15.72M | 17.09M | 21.65M | 23.62M | 23.22M | 22.04M | 16.65M | 15.63M | 12.13M | 10.72M | 9.41M | 8.84M | 9.92M | 8.31M | 8.70M | - | 9.54M | 10.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 27.58M | 46.25M | 62.56M | 73.39M | 65.90M | 82.06M | 97.61M |
| Gross Profit | -20.89M | -61.22M | 17.05M | 39.46M | 16.86M | 48.83M | 45.73M |
| Operating Income | -102.30M | -161.62M | -192.73M | -193.02M | -145.61M | -74.41M | -86.42M |
| Net Income | -99.70M | -162.75M | -32.41M | -168.72M | -133.70M | -72.49M | -77.06M |
| Diluted EPS | -17.08 | -26.87 | -0.19 | -0.84 | -0.65 | -0.34 | -0.31 |
| R&D Expense | 48.93M | 49.74M | 74.46M | 88.04M | 55.62M | 37.80M | 36.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Feb 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 147.19M | 571.97M | 417.57M | 304.27M | 256.08M | 296.53M |
| Total Equity | -118.94M | -212.28M | 0 | -361.93M | 447.69M | 325.36M | 220.05M | 168.83M | 195.98M |
| Cash & Equivalents | - | 90.00M | - | 60.21M | 422.84M | 162.56M | 134.44M | 88.78M | 150.49M |
| Total Liabilities | - | - | - | 148.19M | 124.27M | 92.21M | 84.22M | 87.25M | 100.55M |
| Current Liabilities | - | - | - | 69.69M | 49.83M | 51.33M | 44.27M | 48.22M | 65.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -120.43M | -81.70M | -189.19M | -169.12M | -98.82M | -41.71M | -12.70M |
| Investing Cash Flow | -4.47M | -2.38M | -9.87M | -93.78M | 70.41M | -2.66M | -3.35M |
| Financing Cash Flow | 324.00K | 54.28M | 565.69M | 2.88M | 228.00K | -1.50M | 77.76M |
| Capital Expenditure | -4.47M | -2.38M | -7.88M | -18.30M | -5.78M | -2.69M | -3.35M |
| Free Cash Flow | -124.90M | -84.08M | -197.06M | -187.42M | -104.60M | -44.40M | -16.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | -75.8% | -132.4% | 27.3% | 53.8% | 25.6% | 59.5% | 46.9% |
| Operating Margin % | -370.9% | -349.4% | -308.0% | -263.0% | -221.0% | -90.7% | -88.5% |
| Net Margin % | -361.4% | -351.9% | -51.8% | -229.9% | -202.9% | -88.3% | -79.0% |
| ROE % | 47.0% | 45.0% | -7.2% | -51.9% | -60.8% | -42.9% | -39.3% |
| ROCE % | - | -208.6% | -36.9% | -52.7% | -56.0% | -35.8% | -37.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.69% | 18.82M | $155.28M |
| 2 | Glenview Capital Management, Llc | 5.85% | 14.34M | $118.26M |
| 3 | Hood River Capital Management LLC | 5.39% | 13.19M | $108.82M |
| 4 | Fosun International Ltd | 4.18% | 10.23M | $84.44M |
| 5 | Vanguard Capital Management LLC | 3.50% | 8.56M | $70.61M |
| 6 | Shaw D.E. & Co., Inc. | 2.61% | 6.39M | $52.74M |
| 7 | State Street Corporation | 2.35% | 5.76M | $47.54M |
| 8 | Geode Capital Management, LLC | 2.18% | 5.35M | $44.10M |
| 9 | ARK Investment Management, LLC | 2.08% | 5.09M | $41.96M |
| 10 | Nuveen, LLC | 2.07% | 5.06M | $41.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BFLY
Butterfly Network, Inc. (BFLY) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBsQ05wU0lBMHEtMy1tdGszazVRSTh4bDdid1NlU25ycHRGYnlFSVlLRWdaOEtxbm5yVHdldWowRFhDVFdwN01ONjlYNFpHRlhPVXc?oc=5" target="_blank">Butterfly Network, Inc. (BFLY) Stock Price, News, Quote …
Butterfly Network, Inc. Estimates – NYSE:BFLY - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFA5dEdyVHBaREtTWGdiQ25zMWpUSGNzQUdqUDctRk9uQjdtX1h4Sl9ZYmxkU19LcEV6Ylc2Wm00bVFZZDYzSFZIVEswWWQyM1cyZmltNXdOQVNNNS1BV1BsM2Y2bDdWc2VqUnBWYV9MU1dLeE9hTnc?oc=5" target="_blank">Butterfl…
Butterfly Network Inc. Class A Common Stock (BFLY) Stock Price Today: $6.79 - Pluang
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFBCblY2T0JTYWd1RVdjMVp2QzZPZ3UycXFQejNqZ1NydUxzRlBPY2trX0JVR2Jsbm1KSExqWVk4OHBYX2RJandGdk5fQ1hkUmdwYzBuMzlWS0d2UQ?oc=5" target="_blank">Butterfly Network Inc. Class A Common Stock (…
Is VCOM Ultrasound Deal Altering The Investment Case For Butterfly Network (BFLY)? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNTDZFNlBHZlFyYUlCcnp6ak1obUVOcDhiNEVrMXBVbUVSVFcwMkpvNkFid09ZS1VoZHpuS3I0TzBfb1FPWUNNamdibkdtRjR6VDN5a21oZ2xzVUZ0OGdBUjRUcVdUUlM3dFFRbElqVF9zVGE4WGQ5Zkc4UTZ2RktOYUl5OGdYZW9pVGVHcW…
Butterfly Network, Inc. Class A Actuals & Estimates (NYSE:BFLY) - TradingView
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOaU5wSTlqQkp0MTRINFB4OVVJTjhOVENqMmVUeHhuTFlPcnNvQ2VUZXZEbko0ZWhCb1k4Q2VmcEJvVUd0M19haHBseUZUTFc2dGhZcTl6cmtpMnMyWmRWXzBUZWtlVG9heFlGcE9TLVJNNTB3dVpWcXlTbnRnazMyVE5yNA?oc=5" targe…
BFLY Jan 2029 17.500 call (BFLY290119C00017500) Interactive Stock Chart - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5xRnByd3I4bnc0YUs5LWpPYzVmQzBXaGlWSXlrM2VHNTlldjV2RG5Ra0owb2F3MWtxOG0ta2Vtb0N4VjZ5ZGp4NjFtTVg4M21qRVJuOHVKWEdqRFFuekhLaDBtNG1jN2VVV1JuUHN3?oc=5" target="_blank">BFLY Jan 2029 17.50…
BFLY — Frequently Asked Questions
What is the current share price of Butterfly Network, Inc. (BFLY)?
As of 2026-10-23 16:27 PDT, Butterfly Network, Inc. (BFLY) trades at $6.76 on NYSE. Its 52-week range is $1.50 to $9.93.
What is the market capitalisation of BFLY?
Butterfly Network, Inc. (BFLY) has a market capitalisation of $1.66B on NYSE.
What is the P/E ratio of BFLY?
BFLY trades at a trailing price-to-earnings (P/E) ratio of -23.31. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 11.52.
What is the return on equity (ROE) of BFLY?
BFLY has a return on equity (ROE) of -35.46%. Its return on capital employed (ROCE) is -37.34%.
Is BFLY a good stock to buy?
This page provides a data-driven analysis of Butterfly Network, Inc. (BFLY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.